Magnetic Resonance Imaging Switches as Theranostic Agents
This project will facilitate tracking of a polymer nanomedicine in vivo using both the newly developed 19F MRI technology along with other imaging modalities e.g. PET. The novel imaging approach uses a therapeutic-carrying 19F MR imaging agent. The imaging agent is capable of releasing a therapeutic payload under acidic pH conditions, upon which the agent is switched ‘ON’ and can then be imaged using 19F MRI. The lack of endogenous fluorine in the body means that the contrast agent will be visualised as a bright spot within the MRI resonator. In combination with PET radionuclide imaging, this material provides a useful tool for monitoring biodistribution, accumulation and release of therapeutics in tumour models.